CRSP - CRISPR Therapeutics AG
Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therapeutics for a couple of the firm's funds. While it's typically considered a gene-editing play (and even named after the underlying genomic science), that's not all this biotechnology outfit is working on.
Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,853,875 shares of the company's stock after selling 104,236 shares during the quarter. CRISPR
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.
CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.
CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.
Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.